Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.
|Original language||English (US)|
|Number of pages||4|
|Journal||Inflammatory bowel diseases|
|State||Published - Jun 2005|
ASJC Scopus subject areas
- Immunology and Allergy